Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Lemonaid Health vs myRocky

Lemonaid Health
Graded #488

Lower grade

vs+0.19999999999999574
myRocky
Graded #487

Higher grade

The verdict

myRocky takes it — 51.4/100 to 51.2/100, but only just.

myRocky grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. myRocky is a Canadian-incorporated multi-product telehealth platform (Rocky Health Inc., Ontario) that markets brand-name GLP-1s — Ozempic, Mounjaro, and Wegovy — to US patients, with no compounded products. Lemonaid Health is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valuemyRocky +14
20
34
Dose & formulationmyRocky +1
52
53
Clinical oversightLemonaid Health +10
74
64
Labs & monitoringLemonaid Health +1
53
52
FulfillmentLemonaid Health +11
81
70
Contract termsEven
41
41
Lemonaid Health · left barmyRocky · right bar

The numbers

MetricLemonaid HealthmyRocky
WeighScore51.2/10051.4/100
GradeCC
Scorecard rank#488#487
Semaglutide$348/mo (starting dose, plus a separate fee, compounded)Not disclosed
TirzepatideNot disclosedNot disclosed
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyInjection only
Lemonaid Health

Graded #488 · C

Strengths

  • Aggressively low monthly pricing
  • Both semaglutide and tirzepatide available
  • Compounded GLP-1 access

Where it loses points

  • Limited public information on program details
myRocky

Graded #487 · C

Strengths

  • Brand-name FDA-approved GLP-1s (Ozempic, Mounjaro, Wegovy) on one platform — no compounded-product risk
  • LegitScript Approved
  • 42-state coverage with an 8-state expansion roadmap published
  • Multi-product platform for patients managing GLP-1 plus sexual health, hair loss, or mental health on one subscription

Where it loses points

  • Expensive stacked fees: $99 consult + $99/mo program fee + ~$1,409/mo medication = ~$1,508/mo
  • Canadian incorporation (Rocky Health Inc., Mississauga, ON) — verify your state's prescriber holds an active US license
  • Listed pharmacy is a Canadian community pharmacy; US-fulfillment supply chain not transparent
  • Brand-only — no compounded option for cost-sensitive patients
  • $1,409/mo Ozempic is near retail; compare NovoCare ($349/mo Wegovy pen) or LillyDirect ($449–$699/mo Zepbound)

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard